Serum neurone-specific enolase levels in patients with neuroendocrine and carcinoid tumours.
We have examined concentrations of neurone-specific enolase (NSE) in sera from 18 patients with various neuroendocrine tumours, 26 patients with carcinoid tumours, 21 patients with non-neuroendocrine tumours and 37 control individuals. No statistically significant difference between the concentrations in patients with neuroendocrine tumours and patients with carcinoid tumours was found. However the NSE concentrations in patients with carcinoid and neuroendocrine tumours, when these two groups were combined, were significantly different from the patients with non-neuroendocrine tumours or the control individuals (P < or = 0.01). 38.5% of the patients with carcinoid tumours had raised NSE concentrations in serum; 55.5% of those with non carcinoid neuroendocrine tumours had raised concentrations. There appeared to be no correlation between the NSE concentrations and the extent of metastases.
Cunningham
R T
RT
Department of Medicine, Queen's University of Belfast, Northern Ireland, UK.
Johnston
C F
CF
Irvine
G B
GB
Buchanan
K D
KD
D000328:Adult; D000368:Aged; D002276:Carcinoid Tumor / Q000201:enzymology*; D004701:Endocrine Gland Neoplasms / Q000201:enzymology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009423:Nervous System Neoplasms / Q000201:enzymology*; D010751:Phosphopyruvate Hydratase / Q000097:blood*
D010751:Phosphopyruvate Hydratase